Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGER: Tiragolumab, Atezolizumab, and RadScopal Radiation in Advanced Solid Malignancies
NCT06760481Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2025
- Primary completion
- Sep 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tiragolumab in Advanced malignant solid neoplasm (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Started Apr 2025; status: active, not recruiting.
02
Drugs
tiragolumab
03
Conditions
Advanced malignant solid neoplasm
Beyond the preview
Go deeper on NCT06760481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760481.